Abstracts tagged "Outcome measures"

Abstract Number: 0781 • ACR Convergence 2021
Long-Term Follow-up of Juvenile Localized Scleroderma Patients Treated with Methotrexate-Based Standardized Regimens (Consensus Treatment Plans)
Suzanne Li¹, Aaron Thammavongxay², Maria Ibarra³, Kathryn Torok⁴, Polly Ferguson⁵, C Egla Rabinovich⁶, Robert Fuhlbrigge⁷, Katie Stewart⁸, Elena Pope⁹, Ronald Laxer¹⁰, Sandy Hong¹¹, Thomas Mason¹², Mara Becker¹³, Gloria Higgins¹⁴, Fatma Dedeoglu¹⁵ and for the CARRA Legacy Registry¹⁶, ¹Hackensack Meridian School of Medicine, Joseph M. Sanzari Children's Hospital, West Orange, NJ, ²Bergen Academies, Hackensack, NJ, ³Children's Mercy Hospital, Kansas City, MO, ⁴University of Pittsburgh, Pittsburgh, PA, ⁵University of Iowa Carver College of Medicine, Iowa City, IA, ⁶Duke Childrens Hospital & Health Center, Durham, NC, ⁷University of Colorado, Denver, CO, ⁸UT Southwestern, Dallas, TX, ⁹Hospital for Sick Kids, Toronto, ON, Canada, ¹⁰SickKids, Toronto, ON, Canada, ¹¹University of Iowa Stead Family Children's Hospital, Iowa City, IA, ¹²Mayo Clinic, Rochester, MN, ¹³Duke University Medical Center/Duke Clinical Research Institute, Chapel Hill, NC, ¹⁴Ohio State University, Columbus, OH, ¹⁵Boston Children's Hospital, Boston, MA, ¹⁶Childhood Arthritis and Rheumatology Research Alliance, Milwaukee, WI
Background/Purpose: Juvenile localized scleroderma (jLS) is a rare chronic inflammatory and fibrosing disease associated with a high risk for morbidity in children. Methotrexate (MTX) has…
Abstract Number: 1226 • ACR Convergence 2021
The Neuro-QOL Upper Extremity Function Scale: New Opportunities to More Reliably and Precisely Measure Self-reported Hand Function and Self-care Activities in People with RA
Susan Bartlett¹, Orit Schieir², Marie-France Valois¹, Janet Pope³, Gilles Boire⁴, Edward Keystone⁵, Diane Tin⁶, Carter Thorne⁷, Carol Hitchon⁸, Louis Bessette⁹, Glen Hazlewood¹⁰, Vivian Bykerk¹¹ and CATCH Investigators¹², ¹McGill University, Montréal, QC, Canada, ²Canadian Early Arthritis Cohort Study, Montréal, QC, Canada, ³University of Western Ontario, London, ON, Canada, ⁴Universite de Sherbrooke, Sherbrooke, QC, Canada, ⁵Keystone Consulting Enterprises Inc., Toronto, ON, Canada, ⁶The Arthritis Program Research Group, Newmarket, ON, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸University of Manitoba, Winnipeg, MB, Canada, ⁹Centre de l'Ostoporose et de Rhumatologie de Qubec, Québec City, QC, Canada, ¹⁰University of Calgary, Calgary, AB, Canada, ¹¹Hospital for Special Surgery, New York, NY, ¹²Canadian Early Arthritis Cohort Investigators, Toronto, ON, Canada
Background/Purpose: RA is an inflammatory disease that results in pain and loss of function, especially in the hands and wrists. Brief self-assessment tools that can…
Abstract Number: 1729 • ACR Convergence 2021
Predicting Adverse Pregnancy Outcomes in Women with Systemic Lupus Erythematosus (SLE) Using 2nd Trimester Estimated Glomerular Filtration Rate (eGFR)
Anika Lucas¹, Amanda Eudy¹, Michelle Petri², Rebecca Fischer-Betz³, Abeer Nabil⁴, Cecilia Nalli⁵, Laura Andreoli⁶, Angela Tincani⁷, Yair Molad⁸, Stephen Balevic¹ and Megan Clowse⁹, ¹Duke University, Durham, NC, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Uniklinik Dsseldorf, Dsseldorf, Germany, ⁴University of Cairo, Cairo, Egypt, ⁵ASST SPEDALI CIVILI DI BRESCIA, Brescia, Italy, ⁶University of Brescia, Brescia, Italy, ⁷ASST Spedali Civili-University of Brescia, Gussago, Italy, ⁸Rabin Medical Center, Beilinson Hospital, and Tel Aviv University, Petah-Tikva, Israel, ⁹Duke University, Chapel Hill, NC
Background/Purpose: Women with SLE are at increased risk for adverse maternal and fetal outcomes with increased odds of preeclampsia, hypertension, Cesarean and preterm deliveries, low…
Abstract Number: 0130 • ACR Convergence 2021
Clinical and Economic Characterization of Systemic Lupus Erythematosus Patients: Real World Observation Across Disease Severity and Payer Channels in the U.S
Joseph Tkacz¹, Allison Perry¹, Helen Varker¹, Richard Bizier¹, Robert Ortmann² and Sandra Sze-jung Wu³, ¹IBM Watson Health, Bethesda, MD, ²AstraZeneca, Greenwood, IN, ³AstraZeneca, Wilmington, DE
Background/Purpose: Current literature characterizing the economic and clinical burden of systemic lupus erythematosus (SLE) is outdated and often does not consider SLE disease severity, which…
Abstract Number: 0653 • ACR Convergence 2021
Adherence to the 2015 ACR Guidelines for the Management of Polymyalgia Rheumatica and Screening for Osteoporosis at a Tertiary Care Medical Center
Padmini Parameswaran¹ and Michael Lucke², ¹Allegheny Health Network Medical Education Consortium, Pittsburgh, PA, ²Allegheny Health Network, Pittsburgh, PA
Background/Purpose: Since the first description of polymyalgia rheumatica (PMR) in the early 1950s, the ideal dose and duration of glucocorticoid therapy has varied. In 2015,…
Abstract Number: 0791 • ACR Convergence 2021
Most Rheumatoid Arthritis (RA) Patients from Routine Care Reported in 2008-2021 Have Improved Outcomes vs Earlier Eras, but Most Remain in Moderate/high Disease Activity Rather Than Low Activity/remission: Are New Strategies for Earlier Treatment Needed in Addition to New Agents?
Juan Schmukler¹, Kyle Schroeder² and Theodore Pincus², ¹Mount Sinai Hospital - Rheumatology, Chicago, IL, ²Rush University Medical Center, Chicago, IL
Background/Purpose: Treatment of rheumatoid arthritis (RA) has been advanced considerably by biological agents with capacity for stringent control of inflammation. A “treat-to-target” directive toward remission…
Abstract Number: 1257 • ACR Convergence 2021
Improvements in Abnormal Laboratory Tests Are Associated with Clinical Outcomes in Patients with Active Systemic Lupus Erythematosus
Kathryn Connelly¹, Rangi Kandane-Rathnayake¹, Alberta Hoi², Worawit Louthrenoo³, Laniyati Hamijoyo⁴, Jiacai Cho⁵, Aisha Lateef⁶, Shue-Fen Luo⁷, Yeong-Jian Wu⁸, Zhanguo Li⁹, Yuan An⁹, Sandra Navarra¹⁰, Leonid Zamora¹⁰, Sargunan Sockalingam¹¹, Yanjie Hao¹², Zhuoli Zhang¹², Yasuhiro Katsumata¹³, Masayoshi Harigai¹³, Shereen Oon¹⁴, Madelynn Chan¹⁵, YI-HSING CHEN¹⁶, Sang-Cheol Bae¹⁷, Sean O’Neill¹⁸, Kathryn Gibson¹⁸, Fiona Goldblatt¹⁹, Jun Kikuchi²⁰, Tsutomu Takeuchi²¹, Kristine (Pek Ling) Ng²², Nicola Tugnet²³, B.M.D.B. Basnayake²⁴, Yoshiya Tanaka²⁵, C.S. Lau²⁶, Mandana Nikpour²⁷, Vera Golder¹ and Eric Morand²⁸, ¹Monash University, Clayton, Australia, ²Department of Rheumatology, Monash Health & Department of Medicine, School of Clinical Sciences, Monash University, Melbourne, Australia, ³Maharaj Nakorn Chiangmai, Chiang Mai, Thailand, ⁴University of Padjadjaran, Bandung, Indonesia, ⁵National University Health System (NUHS), Singapore, Singapore, ⁶National University Hospital, Singapore, Singapore, ⁷Chang Gung Memorial Hospital, Taipei, Taiwan, ⁸Chang Gung Memorial Hospital, Taoyuan County, Taiwan, ⁹People's Hospital, Peking University Health Science Center, Beijing, China (People's Republic), ¹⁰University of Santo Tomas Hospital, Manila, Philippines, ¹¹University of Malaya, Kuala Lumpur, Malaysia, ¹²Peking University First Hospital, Beijing, China (People's Republic), ¹³Tokyo Women's Medical University School of Medicine, Tokyo, Japan, ¹⁴Melbourne Health, Parkville, Australia, ¹⁵Tan Tock Seng Hospital, Singapore, Singapore, ¹⁶Taichung Veterans General Hospital, Taichung, Taiwan (Republic of China), ¹⁷Hanyang University Medical Center, Seoul, Republic of Korea, ¹⁸Liverpool Hospital, Sydney, Australia, ¹⁹Flinders Medical Centre, Adelaide, Australia, ²⁰Keio University School of Medicine, Tokyo, Japan, ²¹Div. Rheumatology, Keio University, Tokyo, Japan, ²²North Shore Hospital, Auckland, New Zealand, ²³Auckland District Health Board, Auckland, New Zealand, ²⁴Teaching (General) Hospital, Kandy, Sri Lanka, ²⁵University of Occupational and Environmental Health, Kitakyushu, Japan, ²⁶University of Hong Kong, Hong Kong, Hong Kong, ²⁷University of Melbourne at St Vincent's Hospital, Melbourne, Australia, ²⁸School of Clinical Sciences at Monash Health, Monash University Faculty of Medicine, Nursing and Health Sciences, Monash Medical Centre Clayton, Melbourne, Australia
Background/Purpose: Laboratory tests are routine in the management of SLE. In clinical trial endpoints, data from laboratory tests contribute to responder status, but this is…
Abstract Number: 1773 • ACR Convergence 2021
Comparing Efficacy of Guselkumab versus Ustekinumab in Patients with Psoriatic Arthritis: An Adjusted Comparison Using Individual Patient Data from DISCOVER 1&2 and PSUMMIT Trials
Joris Diels¹, Pushpike Thilakarathne², Agata Schubert³, Fareen Hassan⁴, Steven Peterson⁵ and Wim Noël¹, ¹Janssen Pharmaceutica, HEMAR Department, Beerse, Belgium, ²JanssenCilag Ltd, HEMAR Department, Beerse, Belgium, ³Janssen-Cilag Poland, HEMAR Department, Warsaw, Poland, ⁴Janssen-Cilag Ltd, HEMAR Department, High Wycombe, United Kingdom, ⁵Janssen Immunology Global Commercial Strategy Organization, Raritan, NJ
Background/Purpose: Guselkumab is an anti-interleukin (IL)-23 monoclonal antibody recently approved for the treatment of psoriatic arthritis (PsA). In two large Phase III trials of patients…
Abstract Number: 0256 • ACR Convergence 2021
Consensus Approach to a Treat to Target Strategy in Juvenile Idiopathic Arthritis Care: Report from the 2020 Pediatric Rheumatology Care and Outcomes Improvement Network Consensus Conference
Tala El Tal¹, Meghan Ryan², Brian Feldman³, Catherine Bingham⁴, Jon Burnham⁵, Michelle Batthish⁶, Danielle Bullock⁷, Kerry Ferraro⁸, Mileka Gilbert⁹, Beth Gottlieb¹⁰, Julia Harris¹¹, Melissa Hazen¹², Ronald Laxer¹³, Tzielan Lee¹⁴, Daniel Lovell¹⁵, Melissa Mannion¹⁶, Laura Noonan¹⁷, Edward Oberle¹⁸, Anne Paul¹⁹, Janalee Taylor²⁰, Jennifer Weiss²¹, Cagri Yildirim-Toruner²² and Esi Morgan²³, ¹University of Toronto/Hospital for Sick Children, Toronto, ON, Canada, ²University of Minnesota, Vadnais Heights, MN, ³The Hospital for Sick Children, Toronto, ON, Canada, ⁴Penn State Children's Hospital, Allentown, PA, ⁵Children's Hospital of Philadelphia, Philadelphia, PA, ⁶McMaster University, Hamilton, ON, Canada, ⁷University of Minnesota, Minneapolis, MN, ⁸Pediatric Rheumatology Care and Outcomes Improvement Network, Cincinnati, OH, ⁹Medical University of South Carolina, Charleston, SC, ¹⁰Cohen Children's Medical Center, Lake Success, NY, ¹¹Children's Mercy Kansas City, Overland Park, KS, ¹²Boston Children's Hospital, Boston, MA, ¹³SickKids, Toronto, ON, Canada, ¹⁴Stanford University School of Medicine, Palo Alto, CA, ¹⁵Cincinnati Children’s Hospital Medical Center, University of Cincinnati, Cincinnati, OH, ¹⁶University of Alabama at Birmingham, Birmingham, AL, ¹⁷Levine Children's Hospital/Carolinas Healthcare System, Charlotte, NC, ¹⁸Nationwide Children's Hospital, Columbus, OH, ¹⁹Cincinnati Children's Hospital Medical Centre, Cincinnati, OH, ²⁰Cincinnati Children's Hospital, Cincinnati, OH, ²¹Hackensack University Medical Center, Hackensack, NJ, ²²Texas Children's Hospital/Baylor College of Medicine, Houston, TX, ²³Seattle Children's Hospital, Seattle, WA
Background/Purpose: Treat to target (T2T) is a strategy of adjusting treatment until a therapeutic target is reached. There is growing evidence supporting the use and…
Abstract Number: 0658 • ACR Convergence 2021
ACCORD: A Novel Rheumatology Transition Clinic Structure for Adolescent and Young Adult Patients with Childhood Onset Rheumatic Disease
Rebecca Overbury¹, Kelly Huynh², Tracy Frech¹, John Bohnsack¹ and Aimee Hersh¹, ¹University of Utah, Salt Lake City, UT, ²Intermountain Health Care, Salt Lake City, UT
Background/Purpose: The transition of health care from Pediatric to Adult providers for adolescents and young adults with childhood onset rheumatic disease continues to be associated…
Abstract Number: 0792 • ACR Convergence 2021
Remission Rates of Patients with Rheumatoid Arthritis in a Tertiary Care
Nils Gildemeister¹, Imke Redeker², Bjoern Buehring¹, Ioana Andreica¹, David Kiefer³, Xenofon Baraliakos¹, Juergen Braun¹ and Uta Kiltz¹, ¹Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Herne, Germany, ²German Rheumatism Research Centre (DRFZ), Berlin, Germany, ³Rheumazentrum Ruhrgebiet Herne, Ruhr-Universität Bochum, Essen, Germany
Background/Purpose: The main goal of treatment for patients (pts.) with rheumatoid arthritis (RA) is to achieve remission, in order to both, preserve physical function and…
Abstract Number: 1258 • ACR Convergence 2021
Measurement of Specific Organ Domains in Lupus Randomised Controlled Trials
Kathryn Connelly¹, Jeevan Vettivel², Vera Golder², Rangi Kandane-Rathnayake² and Eric Morand³, ¹Monash University, Camberwell, Australia, ²Monash University, Clayton, Australia, ³Monash University, Melbourne, Australia
Background/Purpose: Randomised controlled trials (RCTs) in SLE typically adopt composite responder definitions as primary efficacy endpoints, however outcomes within individual organ domains are also important…
Abstract Number: 1809 • ACR Convergence 2021
Efficacy of Tofacitinib on Enthesitis in Patients with Active Psoriatic Arthritis
Philip Mease¹, Ana-Maria Orbai², Oliver FitzGerald³, Mohamed Bedaiwi⁴, Dona L Fleishaker⁵, Rajiv Mundayat⁶, Pamela Young⁷ and Philip S Helliwell⁸, ¹Swedish Medical Center/Providence St. Joseph Health and University of Washington, Seattle, WA, ²Division of Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD, ³Conway Institute for Biomolecular Research, University College Dublin, Dublin, Ireland, ⁴Division of Rheumatology, College of Medicine, King Saud University Medical City, Riyadh, Saudi Arabia, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, New York, NY, ⁷Pfizer Inc, Collegeville, PA, ⁸Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, Leeds, United Kingdom
Background/Purpose: Enthesitis (inflammation where the tendon, ligament, or joint capsule insert into the bone) has been associated with higher disease activity and reduced quality of…
Abstract Number: 0320 • ACR Convergence 2021
Performance of the Clinical Trials ESSDAI (ClinTrialsESSDAI), an Adjusted ESSDAI Score, in Two Randomised Clinical Trials in Patients with Primary Sjögren’s Syndrome
Liseth de Wolff¹, Suzanne Arends², Elena Pontarini³, Michele Bombardieri³, Simon J Bowman⁴ and Hendrika Bootsma², ¹University Medical Centre Groningen, Groningen, Netherlands, ²University Medical Center Groningen, Groningen, Netherlands, ³Queen Mary University of London, William Harvey Research Institute, London, United Kingdom, ⁴Department of Rheumatology, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom
Background/Purpose: Recent randomised controlled trials (RCTs) in primary Sjögren’s syndrome (pSS) failed to show clinical efficacy.1-3 Several RCTs used the EULAR Sjögren’s Syndrome Disease Activity…
Abstract Number: 0674 • ACR Convergence 2021
A Behavioral Intervention to Improve Gout Outcomes in African Americans with Gout: A 12-month Multicenter, Randomized Controlled Trial
Jasvinder Singh¹, Kenneth Saag¹, Joshua Baker², Amy Joseph³, Seth Eisen⁴ and Terence Shaneyfelt¹, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Pennsylvania, Philadelphia, PA, ³Washington University / St. Louis VA, St Louis, MO, ⁴Washington University School of Medicine, St Louis, MO
Background/Purpose: Gout outcomes and severity are worst in African Americans compared to Caucasians with gout. Racial Disparities in gout are well-described. Few or no data…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].